

# Alain C Mita

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4974817/publications.pdf>

Version: 2024-02-01

67  
papers

3,529  
citations

257450

24  
h-index

155660

55  
g-index

68  
all docs

68  
docs citations

68  
times ranked

6584  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative Nodal Burden and Mortality Across Solid Cancers. Journal of the National Cancer Institute, 2022, 114, 1003-1011.	6.3	4
2	Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results.. Journal of Clinical Oncology, 2022, 40, 3028-3028.	1.6	0
3	A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.. Journal of Clinical Oncology, 2022, 40, 9085-9085.	1.6	1
4	Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update.. Journal of Clinical Oncology, 2022, 40, 2574-2574.	1.6	7
5	Variations in the association of grade with survival across the head and neck cancer landscape. Head and Neck, 2021, 43, 1105-1115.	2.0	7
6	Nodal staging convergence for HPV <sup>v</sup> and HPV+ oropharyngeal carcinoma. Cancer, 2021, 127, 1590-1597.	4.1	8
7	Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.. Journal of Clinical Oncology, 2021, 39, 3084-3084.	1.6	7
8	Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase 1b results from the JAVELIN Solid Tumor trial. , 2021, 9, e002998.		14
9	469â€...A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. , 2021, 9, A498-A498.		2
10	525â€...Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors. , 2021, 9, A555-A555.		1
11	523â€...Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors. , 2021, 9, A553-A553.		7
12	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Research, 2021, 81, 6273-6280.	0.9	30
13	Stage I HPV <sup>v</sup> positive oropharyngeal cancer: Should all patients receive similar treatments?. Cancer, 2020, 126, 58-66.	4.1	10
14	Impact of insurance on survival in patients <sup>â</sup> 65 with head & neck cancer treated with radiotherapy. Clinical Otolaryngology, 2020, 45, 63-72.	1.2	9
15	The role of concomitant chemoradiotherapy in AJCC 7th edition T1-2N1 oropharyngeal carcinoma in the human papillomavirus era. Oral Oncology, 2020, 110, 104882.	1.5	2
16	Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer. Targeted Oncology, 2020, 15, 523-530.	3.6	7
17	Bromodomain inhibitors a decade later: a promise unfulfilled?. British Journal of Cancer, 2020, 123, 1713-1714.	6.4	30
18	Phase 1b clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Research and Treatment, 2020, 184, 53-62.	2.5	64

#	ARTICLE	IF	CITATIONS
19	Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early-Stage Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1555.	7.1	36
20	Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case. <i>JCO Precision Oncology</i> , 2020, 4, 614-619.	3.0	11
21	Correlation of pathologic tumor grade with survival in oral cavity squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18557-e18557.	1.6	0
22	Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence. <i>Oral Oncology</i> , 2019, 99, 104472.	1.5	5
23	A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. <i>PLoS ONE</i> , 2019, 14, e0221994.	2.5	23
24	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 393.	7.1	303
25	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. <i>Oncology</i> , 2019, 97, 102-111.	1.9	67
26	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4888-4897.	7.0	181
27	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
28	Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 530-539.	2.4	9
29	Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. <i>Investigational New Drugs</i> , 2019, 37, 76-86.	2.6	1
30	Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification. <i>Head and Neck</i> , 2018, 40, 1228-1236.	2.0	15
31	Perspectives in Head and Neck Medical Oncology. <i>Cancer Treatment and Research</i> , 2018, 174, 163-185.	0.5	5
32	LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. <i>Cell</i> , 2018, 172, 825-840.e18.	28.9	312
33	Facility Volume and Survival in Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 408-417.	0.8	37
34	Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer. <i>JAMA Oncology</i> , 2018, 4, 985.	7.1	82
35	Human papillomavirus-associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implications. <i>European Journal of Cancer</i> , 2018, 103, 195-204.	2.8	30
36	Quantitative survival impact of composite treatment delays in head and neck cancer. <i>Cancer</i> , 2018, 124, 3154-3162.	4.1	68

#	ARTICLE	IF	CITATIONS
37	A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.. Journal of Clinical Oncology, 2018, 36, 2578-2578.	1.6	19
38	Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.. Journal of Clinical Oncology, 2018, 36, 3095-3095.	1.6	10
39	Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology, 2017, 79, 339-351.	2.3	2
40	Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. European Journal of Cancer, 2017, 76, 36-44.	2.8	64
41	Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. Cancer, 2017, 123, 1555-1565.	4.1	12
42	Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. Cancer, 2017, 123, 4583-4593.	4.1	23
43	Predictors of survival in head and neck mucosal melanoma. Oral Oncology, 2017, 73, 36-42.	1.5	26
44	Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 616-626.	2.6	22
45	Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics. Targeted Oncology, 2017, 12, 623-641.	3.6	47
46	Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer. Cancer, 2017, 123, 3933-3942.	4.1	108
47	Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas. Oncotarget, 2017, 8, 86769-86783.	1.8	21
48	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. Journal of Clinical Oncology, 2017, 35, 2117-2124.	1.6	538
49	Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States. JAMA Oncology, 2016, 2, 1617.	7.1	114
50	Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2016, 22, 3157-3163.	7.0	207
51	Phase Ib study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 2516-2516.	1.6	22
52	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.. Journal of Clinical Oncology, 2016, 34, 4009-4009.	1.6	42
53	Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase Ib trial: Analysis of safety, clinical activity, and PD-L1 expression.. Journal of Clinical Oncology, 2016, 34, 4514-4514.	1.6	18
54	Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.. Journal of Clinical Oncology, 2016, 34, 5533-5533.	1.6	117

#	ARTICLE	IF	CITATIONS
55	Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology, 2016, 34, 8564-8564.	1.6	6
56	Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase 1b trial.. Journal of Clinical Oncology, 2016, 34, 367-367.	1.6	26
57	Phase 1b study of aldoxorubicin + gemcitabine in metastatic solid tumors.. Journal of Clinical Oncology, 2016, 34, 2523-2523.	1.6	0
58	Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2016, 34, 4095-4095.	1.6	0
59	Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus. Molecular Cancer Therapeutics, 2015, 14, 1404-1413.	4.1	17
60	Combined autophagy and HDAC inhibition. Autophagy, 2014, 10, 1403-1414.	9.1	240
61	Pharmacokinetic study of aldoxorubicin in solid tumor patients.. Journal of Clinical Oncology, 2014, 32, e13557-e13557.	1.6	0
62	Phase 1b of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology, 2014, 32, 7601-7601.	1.6	1
63	The effect of tivantinib on QTc interval in subjects with advanced solid tumors and healthy subjects.. Journal of Clinical Oncology, 2014, 32, e13528-e13528.	1.6	0
64	Phase I study of cabazitaxel (Cbz) plus cisplatin (Cis) in patients (pts) with advanced solid tumors: Substudy to evaluate the impact of a strong CYP3A inhibitor (ketoconazole; K) or inducer (rifampicin; I) on Cbz pharmacokinetics. Journal of Clinical Oncology, 2014, 32, 7601-7601.	1.6	0
65	Pharmacokinetic study of aldoxorubicin in solid tumor patients.. Journal of Clinical Oncology, 2013, 31, e13572-e13572.	1.6	0
66	Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?. Clinical Cancer Research, 2012, 18, 6574-6579.	7.0	48
67	Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 723-730.	7.0	314